Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Entero Therapeutics, Inc. (ENTO) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Entero Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1604191.
Total stock buying since 2017: $726,853.
Total stock sales since 2017: $564,405.
Total stock option exercises since 2017: $90,000.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 727 | $465 | 0 | $0 |
| 2024 | 0 | $0 | 5,906 | $19,329 | 0 | $0 |
| 2023 | 0 | $0 | 21,151 | $24,611 | 0 | $0 |
| 2018 | 207,128 | $276,851 | 0 | $0 | 36,000 | $90,000 |
| 2017 | 128,572 | $450,002 | 160,000 | $520,000 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-01 | 0 | $0 | 727 | $465 | 0 | $0 |
| 2024-10 | 0 | $0 | 476 | $212 | 0 | $0 |
| 2024-07 | 0 | $0 | 1,910 | $2,043 | 0 | $0 |
| 2024-04 | 0 | $0 | 249 | $1,052 | 0 | $0 |
| 2024-03 | 0 | $0 | 3,007 | $14,914 | 0 | $0 |
| 2024-01 | 0 | $0 | 264 | $1,108 | 0 | $0 |
| 2023-10 | 0 | $0 | 4,440 | $1,287 | 0 | $0 |
| 2023-09 | 0 | $0 | 10 | $4 | 0 | $0 |
| 2023-08 | 0 | $0 | 6,053 | $1,815 | 0 | $0 |
| 2023-07 | 0 | $0 | 5,326 | $8,201 | 0 | $0 |
| 2023-04 | 0 | $0 | 5,322 | $13,304 | 0 | $0 |
| 2018-12 | 187,128 | $226,851 | 0 | $0 | 0 | $0 |
| 2018-05 | 20,000 | $50,000 | 0 | $0 | 0 | $0 |
| 2018-01 | 0 | $0 | 0 | $0 | 36,000 | $90,000 |
| 2017-06 | 128,572 | $450,002 | 160,000 | $520,000 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-06 | Romano Sarah (Chief Financial Officer) | Sale | 727 | .64 | 465 |
| 2024-10-09 | Romano Sarah (Chief Financial Officer) | Sale | 476 | .45 | 212 |
| 2024-07-02 | Romano Sarah (Chief Financial Officer) | Sale | 621 | 1.07 | 664 |
| 2024-07-02 | Sapirstein James (Chairman and CEO) | Sale | 1,289 | 1.07 | 1,379 |
| 2024-04-01 | Romano Sarah (Chief Financial Officer) | Sale | 75 | 4.23 | 317 |
| 2024-04-01 | Sapirstein James (Chairman and CEO) | Sale | 174 | 4.23 | 735 |
| 2024-03-15 | Romano Sarah (Chief Financial Officer) | Sale | 1,120 | 4.96 | 5,555 |
| 2024-03-15 | Sapirstein James (Chairman and CEO) | Sale | 1,887 | 4.96 | 9,359 |
| 2024-01-12 | Romano Sarah (Chief Financial Officer) | Sale | 98 | 4.20 | 411 |
| 2024-01-12 | Sapirstein James (Chairman, President and CEO) | Sale | 166 | 4.20 | 697 |
| 2023-10-04 | Romano Sarah (Chief Financial Officer) | Sale | 1,676 | .29 | 486 |
| 2023-10-04 | Sapirstein James (President and CEO) | Sale | 2,764 | .29 | 801 |
| 2023-09-15 | Casamento Charles J | Sale | 10 | .43 | 4 |
| 2023-08-31 | Casamento Charles J | Sale | 6,053 | .30 | 1,815 |
| 2023-07-03 | Romano Sarah (Chief Financial Officer) | Sale | 1,977 | 1.54 | 3,044 |
| 2023-07-03 | Sapirstein James (President and CEO) | Sale | 3,349 | 1.54 | 5,157 |
| 2023-04-03 | Romano Sarah (Chief Financial Officer) | Sale | 1,975 | 2.50 | 4,937 |
| 2023-04-03 | Sapirstein James (President and CEO) | Sale | 3,347 | 2.50 | 8,367 |
| 2018-12-31 | Ross Edmund Burke Jr. | Buy | 23,848 | 1.12 | 26,709 |
| 2018-12-28 | Ross Edmund Burke Jr. | Buy | 29,575 | 1.18 | 34,898 |
| 2018-12-28 | Shenouda Maged (CHIEF FINANCIAL OFFICER) | Buy | 20,000 | 1.31 | 26,220 |
| 2018-12-28 | Spoor Johan M. (PRESIDENT AND CEO) | Buy | 38,583 | 1.29 | 49,964 |
| 2018-12-28 | Casamento Charles J | Buy | 9,000 | 1.41 | 12,690 |
| 2018-12-27 | Ross Edmund Burke Jr. | Buy | 66,122 | 1.16 | 76,370 |
| 2018-05-02 | Ross Edmund Burke Jr. | Buy | 20,000 | 2.50 | 50,000 |
| 2018-01-11 | Borkowski Edward | Option Ex | 36,000 | 2.50 | 90,000 |
| 2017-06-30 | Balk Matthew | Sale | 160,000 | 3.25 | 520,000 |
| 2017-06-05 | Ross Edmund Burke Jr. | Buy | 128,572 | 3.50 | 450,002 |
Insider trading activities including stock purchases, stock sales, and option exercises of ENTO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Entero Therapeutics, Inc. (symbol ENTO, CIK number 1604191) see the Securities and Exchange Commission (SEC) website.